Table 21Pooled odds ratios of outcomes on thiopurine treatment between TPMT variant allele carriers and noncarriers, as well as between the two carrier states (allele specific subgroups)

TPMT alleles testedOutcomeHomozygous carriers vs. noncarriersHeterozygous carriers vs. noncarriersHomozygous carriers vs. heterozygous
N of studies meta-analyzedOdds Ratio (95% CI)N of studies meta-analyzedOdds Ratio (95% CI)N of studies meta- analyzedOdds Ratio (95% CI)
TPMT *2, *3A, *3B, * 3C
InfectionX359,170,1901.37 (0.22 to 8.64)X
WDAEX31,170,1901.06 (0.12 to 9.06)X
Myelotoxicity (11% of patients with events)X251,590.40 (0.05 to 3.33)X
Leukopenia (13% of patients with events)454,172,176,19012.50 (2.29 to 68.00) Favors noncarrier1248,53,54,70,99,157,170, 172,176,186,190,1915. 60 (2.35 to 13.30) Favors noncarriers354,172,1760.68 (0.08 to 5.70)
AnemiaX2157,1701.44 (0.36 to 5.82)X
ThrombocytopeniaX348,157,1903.43 (0.52 to 22.60)X
Hepatitis or raised hepatic transaminases21,544.98 (0.44 to 56.30)81,48,51,52,54,59,70,991.11 (0.39 to 3.10)X
Pancreatitis31,54,1723.27 (0.49 to 21.60)848,51,52,54,59,70,1722.22(0.78 to 6.32)X
TPMT *3A, *3B, *3C
LeukopeniaX246,47,1775.13 (0.82 to 32.00)

I2 > 50% and p- value for test of heterogeneity <0.10
X
Hepatitis or raised hepatic transaminases246,470.98 (0.18 to 5.33)X
PancreatitisX246,470.48 (0.06, 3.60)X
TPMT*1, *2, *3A, *3B, * 3C
LeukopeniaX4173,179–1815.23 (1.99 to 13.70)X

Notes: underlined odds ratios reached statistical significance.

Abbreviations: TPMT = thiopurine methytransferase; vs. = versus; X =absent or insufficient evidence

From: 3, Results

Cover of Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs
Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs.
Evidence Reports/Technology Assessments, No. 196.
Booth RA, Ansari MT, Tricco AC, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.